Actinium Pharmaceuticals Inc (AMEX: ATNM) on Monday, plunged -3.87% from the previous trading day, before settling in for the closing price of $1.55. Within the past 52 weeks, ATNM’s price has moved between $1.03 and $10.24.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -27.50% annually for the last half of the decade. The company achieved an average annual earnings per share of 34.00%. With a float of $30.40 million, this company’s outstanding shares have now reached $31.20 million.
In an organization with 49 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -645.68%, operating margin of -55504.94%, and the pretax margin is -50512.35%.
Actinium Pharmaceuticals Inc (ATNM) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Actinium Pharmaceuticals Inc is 2.54%, while institutional ownership is 28.73%.
Actinium Pharmaceuticals Inc (ATNM) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.38 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 34.00% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 13.33% during the next five years compared to 22.80% growth over the previous five years of trading.
Actinium Pharmaceuticals Inc (AMEX: ATNM) Trading Performance Indicators
Actinium Pharmaceuticals Inc (ATNM) is currently performing well based on its current performance indicators. A quick ratio of 10.25 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 580.98.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.40, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach -1.00 in one year’s time.
Technical Analysis of Actinium Pharmaceuticals Inc (ATNM)
Let’s dig in a bit further. During the last 5-days, its volume was 0.67 million. That was better than the volume of 0.22 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 84.85%. Additionally, its Average True Range was 0.10.
During the past 100 days, Actinium Pharmaceuticals Inc’s (ATNM) raw stochastic average was set at 48.98%, which indicates a significant decrease from 80.39% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 87.91% in the past 14 days, which was higher than the 82.16% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2114, while its 200-day Moving Average is $2.7568. However, in the short run, Actinium Pharmaceuticals Inc’s stock first resistance to watch stands at $1.5867. Second resistance stands at $1.6833. The third major resistance level sits at $1.7767. If the price goes on to break the first support level at $1.3967, it is likely to go to the next support level at $1.3033. The third support level lies at $1.2067 if the price breaches the second support level.
Actinium Pharmaceuticals Inc (AMEX: ATNM) Key Stats
Market capitalization of the company is 46.48 million based on 31,196K outstanding shares. Right now, sales total 80 K and income totals -48,820 K. The company made 0 K in profit during its latest quarter, and -11,570 K in sales during its previous quarter.
